Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide versus radiotherapy for primary treatment of low-grade diffuse glioma
ACTRN12607000427471Phase 3Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, open-label trial of temozolomide in diffuse midline glioma (DMG) and central nervous system tumor (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival. Started Aug 2005; status: active, not recruiting.
02
Drugs
temozolomide
03
Conditions
diffuse midline glioma (DMG)central nervous system tumor
Beyond the preview
Go deeper on ACTRN12607000427471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000427471.